Steven Wulfe

ORCID: 0000-0003-3309-7614
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Hyperglycemia and glycemic control in critically ill and hospitalized patients
  • Blood properties and coagulation
  • Diabetes Management and Research
  • RNA Interference and Gene Delivery
  • Nanoparticle-Based Drug Delivery
  • Inhalation and Respiratory Drug Delivery
  • Diabetes and associated disorders
  • Cystic Fibrosis Research Advances
  • Immunotherapy and Immune Responses
  • Blood Coagulation and Thrombosis Mechanisms
  • Antimicrobial Resistance in Staphylococcus
  • Monoclonal and Polyclonal Antibodies Research
  • Diabetes Treatment and Management
  • Pharmaceutical studies and practices
  • Cell Adhesion Molecules Research
  • Platelet Disorders and Treatments
  • Bacterial biofilms and quorum sensing

Austin College
2022-2025

The University of Texas at Austin
2020-2025

Texas College
2022-2024

University of North Carolina at Chapel Hill
2014-2015

Background: Among people with cystic fibrosis (PwCF), methicillin-resistant Staphylococcus aureus (MRSA)-associated acute pulmonary exacerbations (APEs) have been increasing in prevalence and can cause rapid declines lung function increased mortality. Fortunately, since 2019, incidence has started to decline. Objective: The purpose of this study was evaluate if doxycycline comparable efficacy vancomycin for the treatment APEs PwCF. Given potential toxicities intolerances associated...

10.1177/10600280241310595 article EN Annals of Pharmacotherapy 2025-01-08

Fibrin fibers form the structural backbone of blood clots; fibrinolysis is process in which plasmin digests fibrin fibers, effectively regulating size and duration a clot. To understand clot dissolution, influence structure fiber properties must be separated from effects enzyme kinetics perfusion rates into clots. Using an inverted optical microscope fluorescently-labeled suspended between micropatterned ridges, we have directly measured lysis individual fibers. We found that during 64 ± 6%...

10.1371/journal.pone.0116350 article EN cc-by PLoS ONE 2015-02-25

Although mRNA lipid nanoparticles (LNPs) are highly effective as vaccines, their efficacy for pulmonary delivery has not yet fully been established. A major barrier to this therapeutic goal is instability during aerosolization local delivery. This imparts a shear force that degrades the cargo and therefore reduces cell transfection. In addition remaining stable upon aerosolization, LNPs must also possess aerodynamic properties achieve deposition in clinically relevant areas of lungs. We...

10.1002/btm2.10580 article EN cc-by Bioengineering & Translational Medicine 2023-08-21

Insulin remains a mainstay of treating hyperglycemia in an acute setting. glargine 300 units/mL (Toujeo, iGlar300) has different pharmacokinetic profile than 100 basal insulins, such as insulin detemir (iDet100) and iGlar100. While conversion from iGlar300 to iGlar100 requires 20% dose decrease, there is currently no recommended interchange iDet100.Compare the incidence hypoglycemia patients who received 1:1 unit home or iDet100 while admitted.A retrospective study was conducted evaluate...

10.1177/10600280221119187 article EN Annals of Pharmacotherapy 2022-08-21

Abstract The development and use of concentrated insulins have increased in recent years. This can pose unique challenges when transitioning to a non‐concentrated insulin during an inpatient admission. There is no clear consensus on the recommended interchange various setting, with suggestions ranging from implementing 1:1 unit dose conversion, minimum 20% reduction or selecting approach based total daily insulin. In retrospective cohort analysis at single health system, greater number...

10.1002/jac5.1997 article EN JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY 2024-07-01

Abstract Purpose A previous study at Ascension Seton Hospital Network (ASHN) found a 1:1 dose conversion to insulin detemir 100 units/mL (iDet100) from glargine 300 (iGlar300) increased the incidence of hypoglycemia as compared units/mL. No studies have evaluated an automatic 20% reduction for this specific therapeutic interchange. The purpose was compare rates following implementation protocol specifying minimum when converting iGlar300 inpatient iDet100. Methods This multicenter,...

10.1093/ajhp/zxae346 article EN American Journal of Health-System Pharmacy 2024-11-21
Coming Soon ...